<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Mol Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Mol Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Mol. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Molecular Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5099</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29520219</article-id>
<article-id pub-id-type="pmc">5827687</article-id>
<article-id pub-id-type="doi">10.3389/fnmol.2018.00055</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Plexin-Semaphorin Signaling Modifies Neuromuscular Defects in a <italic>Drosophila</italic> Model of Peripheral Neuropathy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Grice</surname>
<given-names>Stuart J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/528520/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sleigh</surname>
<given-names>James N.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/305081/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zameel Cader</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/463212/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>MRC Functional Genomics Unit, Department of Physiology, Anatomy and Genetics, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country>United Kingdom</country></aff>
<aff id="aff2"><sup>2</sup><institution>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff>
<aff id="aff3"><sup>3</sup><institution>MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country>United Kingdom</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Ildikó Rácz, Universitätsklinikum Bonn, Germany</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Sean T. Sweeney, University of York, United Kingdom; Anuradha Ratnaparkhi, Agharkar Research Institute, India; Krishanu Ray, Tata Institute of Fundamental Research, India</p>
</fn>
<corresp id="fn001">*Correspondence: M. Zameel Cader <email xlink:type="simple">zameel.cader@ndcn.ox.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>11</volume>
<elocation-id>55</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>2</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Grice, Sleigh and Cader.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Grice, Sleigh and Cader</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Dominant mutations in <italic>GARS</italic>, encoding the ubiquitous enzyme glycyl-tRNA synthetase (GlyRS), cause peripheral nerve degeneration and Charcot-Marie-Tooth disease type 2D (CMT2D). This genetic disorder exemplifies a recurring paradigm in neurodegeneration, in which mutations in essential genes cause selective degeneration of the nervous system. Recent evidence suggests that the mechanism underlying CMT2D involves extracellular neomorphic binding of mutant GlyRS to neuronally-expressed proteins. Consistent with this, our previous studies indicate a non-cell autonomous mechanism, whereby mutant GlyRS is secreted and interacts with the neuromuscular junction (NMJ). In this <italic>Drosophila</italic> model for CMT2D, we have previously shown that mutant <italic>gars</italic> expression decreases viability and larval motor function, and causes a concurrent build-up of mutant GlyRS at the larval neuromuscular presynapse. Here, we report additional phenotypes that closely mimic the axonal branching defects of <italic>Drosophila</italic> plexin transmembrane receptor mutants, implying interference of plexin signaling in <italic>gars</italic> mutants. Individual dosage reduction of two <italic>Drosophila</italic> Plexins, <italic>plexin A (plexA)</italic> and <italic>B (plexB)</italic> enhances and represses the viability and larval motor defects caused by mutant GlyRS, respectively. However, we find plexB levels, but not plexA levels, modify mutant GlyRS association with the presynaptic membrane. Furthermore, increasing availability of the plexB ligand, Semaphorin-2a (Sema2a), alleviates the pathology and the build-up of mutant GlyRS, suggesting competition for plexB binding may be occurring between these two ligands. This toxic gain-of-function and subversion of neurodevelopmental processes indicate that signaling pathways governing axonal guidance could be integral to neuropathology and may underlie the non-cell autonomous CMT2D mechanism.</p>
</abstract>
<kwd-group>
<kwd>axonal guidance</kwd>
<kwd>aminoacyl-tRNA synthetase (ARS)</kwd>
<kwd>Charcot-Marie-Tooth disease type 2D (CMT2D)</kwd>
<kwd>distal spinal muscular atrophy type V (dSMA-V)</kwd>
<kwd>
<italic>GARS</italic>
</kwd>
<kwd>glycyl-tRNA synthetase</kwd>
<kwd>neuromuscular disease</kwd>
<kwd>neurodevelopment</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">Medical Research Council<named-content content-type="fundref-id">10.13039/501100000265</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn002">AFM-Téléthon<named-content content-type="fundref-id">10.13039/501100004923</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn003">Wellcome Trust<named-content content-type="fundref-id">10.13039/100004440</named-content></funding-source>
<award-id rid="cn003">103191/Z/13/Z</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="5"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="52"></ref-count>
<page-count count="11"></page-count>
<word-count count="7810"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="introduction">
<title>Introduction</title>
<p>Dominant mutations in the glycyl-tRNA synthetase (GlyRS) gene, <italic>GARS</italic>, cause Charcot-Marie-Tooth disease type 2D (CMT2D; Antonellis et al., <xref ref-type="bibr" rid="B3">2003</xref>). CMT is a broad group of genetically heterogeneous peripheral neuropathies that present with progressive motor and sensory degeneration. Type 1/Demyelinating CMT is typified by demyelination leading to reduced nerve conduction velocities (NCVs), Type 2/Axonal CMTs display axonal loss with relatively normal NCVs, while intermediate forms share clinical features of the two. <italic>GARS</italic> is one of several aminoacyl-tRNA synthetase (ARS) genes linked to CMT (Jordanova et al., <xref ref-type="bibr" rid="B20">2006</xref>; Latour et al., <xref ref-type="bibr" rid="B21">2010</xref>; McLaughlin et al., <xref ref-type="bibr" rid="B24">2010</xref>; Gonzalez et al., <xref ref-type="bibr" rid="B12">2013</xref>; Vester et al., <xref ref-type="bibr" rid="B48">2013</xref>). In total, there are 37 human ARS proteins, which catalyze the covalent linkage of specific amino acids to their partner transfer RNAs (tRNAs; Pang et al., <xref ref-type="bibr" rid="B34">2014</xref>). As GlyRS, and ultimately glycine aminoacylation, is essential in almost all cell types (Antonellis et al., <xref ref-type="bibr" rid="B3">2003</xref>; Alexandrova et al., <xref ref-type="bibr" rid="B2">2015</xref>), the neuronal specificity of the disease is puzzling. A number of potential mechanisms have been hypothesized (Motley et al., <xref ref-type="bibr" rid="B27">2010</xref>; Niehues et al., <xref ref-type="bibr" rid="B31">2015</xref>; Storkebaum, <xref ref-type="bibr" rid="B45">2016</xref>), although the exact pathological processes remain unknown. Notwithstanding, cellular and mouse studies suggest that CMT2D is caused by a gain-of-function in mutant GlyRS rather than <italic>GARS</italic> haploinsufficiency, or loss of canonical glycine aminoacylation or a secondary non-canonical function (Seburn et al., <xref ref-type="bibr" rid="B38">2006</xref>; Nangle et al., <xref ref-type="bibr" rid="B28">2007</xref>; Xie et al., <xref ref-type="bibr" rid="B51">2007</xref>; Achilli et al., <xref ref-type="bibr" rid="B1">2009</xref>; Motley et al., <xref ref-type="bibr" rid="B26">2011</xref>).</p>
<p>Numerous mutations in <italic>GARS</italic> have been shown to cause a similar conformational change to GlyRS, leading to a structure that can bind to erroneous targets (He et al., <xref ref-type="bibr" rid="B16">2011</xref>). Given that GlyRS is secreted (Park et al., <xref ref-type="bibr" rid="B35">2012</xref>; Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>; He et al., <xref ref-type="bibr" rid="B15">2015</xref>), these mis-interactions are not necessarily restricted to within cells. Indeed, recent studies have shown that neomorphic regions in mutant GlyRS facilitate aberrant, extracellular interactions with Neuropilin 1 (Nrp1; He et al., <xref ref-type="bibr" rid="B15">2015</xref>) and the tropomyosin receptor kinase (Trk) receptors (Sleigh et al., <xref ref-type="bibr" rid="B41">2017a</xref>). In conjunction with plexins and other co-receptors, Nrp1 binds to extracellular signaling proteins such as the semaphorins and vascular endothelial growth factor (VEGF), and is part of cell-cell communication that governs the processes guiding the development of both the nervous and vascular systems (Neufeld et al., <xref ref-type="bibr" rid="B29">2002</xref>; Supplementary Figure S1). Similarly, the Trk receptors bind to target-secreted, extracellular growth factors, and play a key role in the development, differentiation and survival of sensory nerves (Lindsay, <xref ref-type="bibr" rid="B23">1996</xref>). The interaction of mutant GlyRS with Nrp1 selectively antagonizes VEGF signaling (He et al., <xref ref-type="bibr" rid="B15">2015</xref>), preferentially impacting the nervous, but not the vasculature, system (Sleigh et al., <xref ref-type="bibr" rid="B42">2017b</xref>). Neomorphic interactions between mutant GlyRS and anomalous targets are thus likely to play an important role in the manifestation of CMT2D.</p>
<p>CMT2D patients generally present during adolescence with progressive muscle weakness in the distal limbs due to axon loss, while NCVs and myelination remain unperturbed (Antonellis et al., <xref ref-type="bibr" rid="B3">2003</xref>; Sivakumar et al., <xref ref-type="bibr" rid="B39">2005</xref>). In addition to axonal degeneration (Seburn et al., <xref ref-type="bibr" rid="B38">2006</xref>; Achilli et al., <xref ref-type="bibr" rid="B1">2009</xref>), CMT2D mice display denervation (Seburn et al., <xref ref-type="bibr" rid="B38">2006</xref>; Achilli et al., <xref ref-type="bibr" rid="B1">2009</xref>; Motley et al., <xref ref-type="bibr" rid="B26">2011</xref>; Sleigh et al., <xref ref-type="bibr" rid="B43">2014b</xref>) and impaired neurotransmission (Spaulding et al., <xref ref-type="bibr" rid="B44">2016</xref>) at the neuromuscular junction (NMJ), which is preceded by defective synaptic development (Sleigh et al., <xref ref-type="bibr" rid="B43">2014b</xref>).</p>
<p>In <italic>Drosophila</italic>, we have shown that mutant GlyRS is secreted by muscle and interacts with the NMJ (Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>). This gain-of-function, non-cell autonomous mechanism causes both degenerative and developmental abnormalities in the <italic>Drosophila</italic> nervous system. The mechanisms underlying these defects remain unknown, but interactions with neuropilin-plexin-semaphorin signaling is an attractive possibility for a number of reasons. First, in vertebrates, mutant GlyRS binds to and interferes with the canonical function of the plexin-interacting protein Nrp1. Second, plexin-semaphorin signaling controls processes perturbed in a number of CMT2D animal models (outlined above) including neurotransmission (Carrillo et al., <xref ref-type="bibr" rid="B7">2010</xref>; Orr et al., <xref ref-type="bibr" rid="B33">2017</xref>), synaptic establishment and maturation (Hu et al., <xref ref-type="bibr" rid="B17">2001</xref>; Ayoob et al., <xref ref-type="bibr" rid="B4">2006</xref>; Berke and Keshishian, <xref ref-type="bibr" rid="B6">2011</xref>), and active zone protein dynamics (Orr et al., <xref ref-type="bibr" rid="B33">2017</xref>). Finally, in this report, characterization of flies expressing mutant <italic>gars</italic> identified phenotypes that mimic those associated with perturbed plexin-semaphorin signaling. Though no direct <italic>Drosophila</italic> ortholog of Nrp1 has been identified, the fly has two plexin genes, <italic>plexin A</italic> (<italic>plexA</italic>; Winberg et al., <xref ref-type="bibr" rid="B49">1998</xref>) and <italic>plexin B</italic> (<italic>plexB</italic>; Hu et al., <xref ref-type="bibr" rid="B17">2001</xref>), which independently bind to different semaphorin classes and are critical to the process of axon guidance (Schuster et al., <xref ref-type="bibr" rid="B37">1996</xref>; Hu et al., <xref ref-type="bibr" rid="B17">2001</xref>), retrograde signaling at the synapse, and synaptic plasticity (Orr et al., <xref ref-type="bibr" rid="B33">2017</xref>).</p>
<p>As mentioned above, we now report that mutant GlyRS expression mimics the axonal branching defects generated by loss-of-function mutations in the two fly plexins, <italic>plexA</italic> and <italic>plexB</italic>. Moreover, we show that dosage reduction of <italic>plexA</italic> and <italic>plexB</italic> enhances and represses the viability and motor function defects caused by mutant <italic>gars</italic> expression, respectively. <italic>plexA</italic> and <italic>plexB</italic> dosage changes also modify adherent axonal protein localization, whilst reduction of <italic>plexB</italic> ameliorates the toxic build-up of GlyRS at the synapse. The centrality of PlexB signaling to mutant GlyRS toxicity is further highlighted by the observation that overexpression of the PlexB ligand, Semaphorin-2a (Sema2a), suppresses mutant GlyRS synaptic binding and associated neuropathology. This reveals an important role for plexins in mutant GlyRS pathology and suggests a possible mechanism by which mutant GlyRS can exert non-cell autonomous effects.</p>
</sec>
<sec id="s2" sec-type="materials and methods">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>General Methods</title>
<p>Reagents were obtained from Sigma-Aldrich unless otherwise stated. All <italic>Drosophila</italic> stocks were cultured on standard molasses/maize meal and agar medium in plastic vials or bottles at 20 or 25°C. The <italic>gars</italic><sup>P234KY</sup> and <italic>gars</italic><sup>wt</sup> stocks have been previously described (Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>). <italic>1032-GAL4</italic>, <italic>elav-GAL4</italic>, <italic>MHC-GAL4</italic>, the plexA loss-of-function mutant <italic>plexA</italic><sup>MB09499</sup>, <italic>UAS-plexA</italic> and the plexB loss-of-function mutant <italic>plexB</italic><sup>KG00878</sup>, were obtained from the Bloomington <italic>Drosophila</italic> Stock Center at Indiana University, and Alex Kolodkin generously shared the <italic>UAS-Sema-1a, UAS-Sema-2a-TM-GFP</italic>, and <italic>UAS-plexB-myc</italic> lines.</p>
</sec>
<sec id="s2-2">
<title><italic>Drosophila</italic> Viability and Behavioral Assays</title>
<p>Adult viability assays were conducted by crossing <italic>GAL4</italic> driver stocks to lines harboring <italic>gars</italic> overexpression or to <italic>w</italic><sup>1118</sup> for controls. Embryos were then counted, lined on apple juice plates with yeast, and larval development noted. Fresh yeast was added daily. Two days post-eclosion the number of surviving adult flies was counted for each genotype. Hundred flies per genotype were scored over three independent experiments. Measurement of motor function involved placing individual age-matched third instar larvae at the center of a 0.7% (w/v) agar plate and counting the forward body wall contractions exhibited in 2 min. Twenty flies per genotype were scored.</p>
</sec>
<sec id="s2-3">
<title><italic>Drosophila</italic> Larval NMJ Analysis</title>
<p>Larvae were reared, dissected and processed as previously described with analysis of hemisegment A2 (Schuster et al., <xref ref-type="bibr" rid="B37">1996</xref>; Grice et al., <xref ref-type="bibr" rid="B13">2015a</xref>,<xref ref-type="bibr" rid="B14">b</xref>), and at least 23 NMJs per genotype per stage were scored. Ectopic branch contact analysis was performed using L3 larval hemisegments A1 to A3, and 14 flies per genotype were scored. For axonal bruchpilot (Brp) localization studies, the transverse nerve (TN) section bypassing muscle 6 and 7 in hemisegments A2 and A3 was used. For immunohistochemistry, anti-discs large (DLG, DSHB), anti-HRP (Jackson), anti-Bruchpilot (DSHB) and anti-HA (Santa Cruz) were all used at 1/100 in combination with secondary antibodies, AlexaFluor 488 goat anti-rabbit and AlexaFluor 633 goat anti-mouse (Invitrogen) at 1/1000. Z-stacks were taken using a Leica SP5 laser confocal microscope and analysis performed using ImageJ and Photoshop (Adobe).</p>
</sec>
<sec id="s2-4">
<title>Quantitative RT-PCR (qPCR)</title>
<p>RNA was extracted from dissected L3 larval ventral nerve cords using an RNeasy Mini Kit (QIAGEN), as per the manufacturer’s instructions, and reverse transcribed as published previously (Sleigh et al., <xref ref-type="bibr" rid="B40">2014a</xref>). cDNA was diluted in water (1/10) before mRNA levels were assessed by qPCR in 20 μl reactions using SYBR Green (Applied Biosystems) and a StepOnePlus real-time PCR machine (Applied Biosystems). Relative gene expression was assessed as previously described (Lee et al., <xref ref-type="bibr" rid="B22">2008</xref>; Sleigh et al., <xref ref-type="bibr" rid="B40">2014a</xref>). Primer sequences were as follows: <italic>plexA</italic> forward 5′-GCT CGT CGT TGA CAA AAT TCG-3′ and reverse 5′-TAA ATG CGA CCC AGA TTG GTG C-3; <italic>plexB</italic> forward 5′-GCG TTT TCA TCG TTA GCA GC-3′and reverse 5′-CAT TCG ACA AGG AGC CTG C-3′. Three technical replicates per reaction were performed, with each of three biological replicates, and expression was normalized to <italic>rp42</italic>.</p>
</sec>
<sec id="s2-5">
<title>Statistical Analysis</title>
<p>When normally distributed, datasets were statistically analyzed using either an unpaired <italic>t</italic>-test with Welch’s correction or a one-way analysis of variance with Bonferroni’s multiple comparison test. If the data did not pass normality testing, the non-parametric Mann–Whitney <italic>U</italic> test or Kruskal–Wallis test with Dunn’s multiple comparison test was used. Linear regression analyses were performed to determine the correlation between synaptic accumulation of mutant GlyRS and neuropathological features of the CMT2D model. GraphPad Prism 5 software was used for all statistical analyses.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3-1">
<title><italic>gars</italic><sup>P234KY</sup> Expression Alters Neurodevelopmental Wiring</title>
<p>We use a <italic>Drosophila</italic> larval model for CMT2D (Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>), and concentrate on neuronal phenotypes in the neuromuscular system caused by the mutant <italic>gars</italic> expression. Both developmental and degenerative defects have been observed in <italic>Drosophila</italic> CMT2D models (Chihara et al., <xref ref-type="bibr" rid="B8">2007</xref>; Ermanoska et al., <xref ref-type="bibr" rid="B10">2014</xref>; Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>; Niehues et al., <xref ref-type="bibr" rid="B31">2015</xref>); however, the causative mechanisms for many of these phenotypes have not been identified. We have previously shown that expression of mutant GlyRS in flies leads to motor deficits and progressive NMJ denervation, mirroring CMT2D mice (Sleigh et al., <xref ref-type="bibr" rid="B43">2014b</xref>, <xref ref-type="bibr" rid="B41">2017a</xref>; Spaulding et al., <xref ref-type="bibr" rid="B44">2016</xref>), as well as presynaptic accumulation of mutant GlyRS (Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>). In addition, we find that the neuronal toxicity is, at least in part, non-cell autonomous (Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>). Furthermore, defects in synaptic establishment, maturation, function and maintenance have been observed in invertebrate (Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>) and vertebrate <italic>Gars</italic> neuropathy models (Sleigh et al., <xref ref-type="bibr" rid="B43">2014b</xref>; Spaulding et al., <xref ref-type="bibr" rid="B44">2016</xref>).</p>
<p>We now report a novel CMT2D phenotype of defective synaptic wiring in the <italic>Drosophila</italic> neuromuscular system. The <italic>Drosophila</italic> larval abdominal ventrolateral muscles 6 and 7 are innervated in a stereotyped manner by defasciculated segmental nerve d (SNd; Figures <xref ref-type="fig" rid="F1">1A,B</xref>). Other proximal nerves, such as the TN and SNb, normally bypass these muscles. In wild-type flies, SNb innervates the adjacent muscle 12, while the TN entirely circumvents muscles 6, 7, 12 and 13. When a mutant form of GlyRS is ubiquitously expressed using the GAL4-UAS system (<italic>1032-GAL4</italic> driver), ectopic synaptic contacts from both the TN (Figures <xref ref-type="fig" rid="F1">1B,C</xref>; Supplementary Figures S2C,D) and SNb (Supplementary Figure S2B) are often observed on muscles 6 and 7 in <italic>gars</italic><sup>P234KY</sup> flies. Consistent with the non-cell autonomous disease mechanism we have previously identified (Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>), this occurs when <italic>gars</italic><sup>P234KY</sup> is expressed from muscle (<italic>MHC-GAL4</italic>; Figure <xref ref-type="fig" rid="F1">1D</xref>), but not neurons (<italic>elav-GAL4</italic>), nor when wild-type <italic>gars</italic> is ubiquitously expressed using the same driver (Figure <xref ref-type="fig" rid="F1">1E</xref>). This indicates that mutant GlyRS disrupts normal axonal guidance, and that this possibly occurs through cell-to-cell signaling rather than disturbance of inherent neuronal pathways. We did not see comparable defects in a model of spinal muscular atrophy (SMA; <italic>Smn</italic><sup>x7</sup>/<italic>Smn</italic><sup>x7</sup>), suggesting that these defects are not general to all <italic>Drosophila</italic> models of motor neuron degeneration.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><italic>gars</italic><sup>P234KY</sup> expression phenocopies plexin mutants and subverts plexin-mediated axonal branching. <bold>(A)</bold> Schematic of the larval ventral body wall muscles in one hemisegment, showing the transverse nerve (TN), and branches of segmental nerves b (SNb) and d (SNd). The ectopic synaptic contacts often observed on muscles 6 and 7 in <italic>gars</italic><sup>P234KY</sup> flies are shown in red. <bold>(B)</bold> In wild-type flies, SNb innervates muscle 12, while the TN entirely bypasses muscles 6, 7, 12 and 13. <bold>(C,D)</bold> Ectopic axons (arrows) and synaptic contacts can be observed from the SNb and the TN when <italic>gars</italic><sup>P234KY</sup> is expressed ubiquitously <bold>(C)</bold> or in muscle <bold>(D)</bold>, phenocopying loss-of-function <italic>plexB</italic> homozygotes (Carrillo et al., <xref ref-type="bibr" rid="B7">2010</xref>). <bold>(E)</bold> Ubiquitous (<italic>1032-GAL4</italic>) and muscle (<italic>MHC-GAL4</italic>) <italic>gars</italic><sup>P234KY</sup> expression, but not mutant neuronal (<italic>elav-GAL4</italic>) or ubiquitous wild-type <italic>gars</italic> expression, lead to an increased number of ectopic contacts in L3 larvae. This is not seen in a model of spinal muscular atrophy (<italic>smn</italic><sup>x7</sup>/<italic>smn</italic><sup>x7</sup>), a second, unrelated neuromuscular condition. Ectopic branches are scored from both the TN and the SNb nerve. <bold>(F)</bold> Expressing <italic>gars</italic><sup>P234KY</sup> with a ubiquitous driver in either a <italic>plexA</italic> or <italic>plexB</italic> heterozygous knockout background significantly enhances the branching defects from the TN nerve. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, Dunn’s multiple comparison test. N.b., <italic>gars</italic><sup>P234KY</sup> is not expressed in the following flies: control, <italic>Smn</italic><sup>x7</sup>/<italic>Smn</italic><sup>x7</sup>, <italic>plexA/+</italic>, <italic>plexB/+</italic>, <italic>Smn</italic><sup>x7</sup>/Smn<sup>x7</sup>; <italic>plexA/+</italic> and <italic>Smn</italic><sup>x7</sup>/Smn<sup>x7</sup>; <italic>plexB/+</italic>
<bold>(E,F)</bold>. Scale bars = 10 μm. For all experiments, <italic>n</italic> &gt; 16 larvae per genotype. Error bars represent ± standard error of the mean (SEM). See also Supplementary Figure S2.</p>
</caption>
<graphic xlink:href="fnmol-11-00055-g0001"></graphic>
</fig>
</sec>
<sec id="s3-2">
<title>Heterozygous <italic>plexA</italic> and <italic>plexB</italic> Mutations Enhance <italic>gars</italic><sup><italic>P234KY</italic></sup> Axonal Branching Defects</title>
<p>A recent study has shown that mutated GlyRS binds to the membrane-bound protein Nrp1 (He et al., <xref ref-type="bibr" rid="B15">2015</xref>), which acts as a co-receptor with mammalian Plexin A for semaphorin signaling (Tran et al., <xref ref-type="bibr" rid="B47">2007</xref>). Whilst there is no direct Nrp1 ortholog, the fly has two plexin orthologs, <italic>plexA</italic> (Winberg et al., <xref ref-type="bibr" rid="B49">1998</xref>) and <italic>plexB</italic> (Hu et al., <xref ref-type="bibr" rid="B17">2001</xref>), which independently bind to different semaphorin classes. Due to their role in axonal attraction and repulsion, knock-down of the <italic>Drosophila</italic> plexins drives diverse axon guidance defects in the embryo, while total loss of the plexin proteins leads to fly lethality (Winberg et al., <xref ref-type="bibr" rid="B49">1998</xref>; Hu et al., <xref ref-type="bibr" rid="B17">2001</xref>; Ayoob et al., <xref ref-type="bibr" rid="B4">2006</xref>). Intriguingly, the CMT2D model presented here (i.e., mutant <italic>gars</italic>-expressing flies), phenocopies the wiring defects of both <italic>plexA</italic> and <italic>plexB</italic> loss-of-function mutants (Figures <xref ref-type="fig" rid="F1">1A–E</xref>). We therefore looked to see if alterations in plexin levels modify the axonal guidance defects observed when <italic>gars</italic><sup>P234KY</sup> is expressed. To reduce plexin levels in mutant <italic>gars</italic> flies, we crossed heterozygous loss-of-function mutants of both <italic>plexA</italic> (<italic>plexA</italic><sup>MB09499</sup>) and <italic>plexB</italic> (<italic>plexB</italic><sup>KG00878</sup>) to flies ubiquitously expressing <italic>gars</italic><sup>P234KY</sup>, and re-scored the number of ectopic contacts occurring between the TN and muscles 6 and 7. We found that heterozygous reduction of both <italic>plexA</italic> and <italic>plexB</italic> enhanced the ectopic branching defects observed in mutant GlyRS flies (Figure <xref ref-type="fig" rid="F1">1F</xref>), suggesting that <italic>gars</italic><sup>P234KY</sup> expression interferes with plexin-mediated axonal guidance. Again, we did not see any modifications in the SMA model (<italic>Smn</italic><sup>x7</sup>/<italic>Smn</italic><sup>x7</sup>), suggesting that the enhancements are specific to the CMT2D model.</p>
</sec>
<sec id="s3-3">
<title>Differential Effects of PlexA and B on <italic>gars</italic><sup><italic>P234KY</italic></sup> Lethality and Motor Dysfunction</title>
<p>Mutant GlyRS causes both larval and adult phenotypes in the fly (Ermanoska et al., <xref ref-type="bibr" rid="B10">2014</xref>; Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>; Niehues et al., <xref ref-type="bibr" rid="B31">2015</xref>); however, the axonal branching defects in both plexin and <italic>gars</italic><sup>P234KY</sup> mutants are likely to originate during embryonic development and larval growth. We therefore assessed <italic>plexA</italic> and <italic>plexB</italic> expression in larval and adult nervous systems using quantitative RT-PCR (qPCR). The RNA of both genes was detected in the larval central nervous system, and the adult brain and ventral nerve cord (Supplementary Figure S3), suggesting that both plexins function throughout life.</p>
<p>We next looked to see how modifying plexin levels impacts the adult lethality and larval motor defects when <italic>gars</italic><sup>P234KY</sup> is expressed ubiquitously using <italic>1032-GAL4</italic> (going forward referred to as <italic>gars</italic><sup>P234KY</sup> flies). Ubiquitous expression of <italic>gars</italic><sup>P234KY</sup> significantly reduced adult viability, with only 7% surviving to the adult stage. We found <italic>plexA</italic> and <italic>plexB</italic> reduction had opposing effects on the adult viability defect of <italic>gars</italic><sup>P234KY</sup> flies: reduction of <italic>plexA</italic> compounded the reduced viability (1% survival), whilst diminishing <italic>plexB</italic> levels significantly improved survival (21% survival). Alternatively, increasing <italic>plexA</italic> had no significant effect, while <italic>plexB</italic> overexpression reciprocally exacerbated the <italic>gars</italic><sup>P234KY</sup> viability phenotype, with no flies (0%) making it to the late pupal stage (Figure <xref ref-type="fig" rid="F2">2A</xref>). These results were corroborated by larval motor function testing (Figure <xref ref-type="fig" rid="F2">2B</xref>). When mutant <italic>gars</italic> is expressed, larval muscular contractions (a surrogate for larval motor function) decrease in number (~20 contractions/min are observed in the mutant compared to ~39 mean in controls). The defects in muscle function of mutant <italic>gars</italic>-expressing flies were worsened in <italic>plexA</italic> heterozygotes (~10 contractions/min) and marginally improved in plexA overexpressors (~27 contractions/min). <italic>PlexB</italic> reduction improved contraction frequency (~28 contractions/min) and <italic>plexB</italic> overexpression exacerbated it (~4 contractions/min). It should be noted that reduced PlexB levels enhanced the wiring defect (Figure <xref ref-type="fig" rid="F1">1F</xref>) but ameliorated the viability and motor phenotypes (Figure <xref ref-type="fig" rid="F2">2</xref>), suggesting that the neurodevelopmental branching defects do not contribute to the reduced viability of <italic>gars</italic><sup>P234KY</sup> flies and that mutant pathology is not due to loss of PlexB function. Due to the severe nature of the adult phenotypes, and given that the <italic>gars</italic><sup>P234KY</sup> flies surviving to adulthood die soon after eclosing, we did not perform movement assays in adults.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Plexin mutants modify glycyl-tRNA synthetase (GlyRS)<sup>P234KY</sup>-associated viability and motor defects. <bold>(A)</bold> Expressing <italic>gars</italic><sup>P234KY</sup> with a ubiquitous driver (<italic>1032-GAL4</italic>) in a <italic>plexB</italic> heterozygous loss-of-function background significantly alleviates adult viability defects, while <italic>plexB</italic> overexpression reciprocally causes full lethality. Contrastingly, <italic>gars</italic><sup>P234KY</sup> expression in a <italic>plexA</italic> loss-of-function background leads to a decrease in viability, while its overexpression has no effect.<bold> (B)</bold>
<italic>gars</italic><sup>P234KY</sup> expression in <italic>plexB</italic> heterozygous larvae partially rescues muscle contractions, whilst <italic>gars</italic><sup>P234KY</sup> expression in a <italic>plexA</italic> background enhanced the motor defect. <italic>plexA</italic> overexpression partially restores movement, while <italic>plexB</italic> overexpression enhances the motor defect. The larval motor defects are thus analogous to the adult viability defects in <bold>(A)</bold>. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001 Dunn’s multiple comparison test. N.b., <italic>gars</italic><sup>P234KY</sup> is not expressed in the <italic>plexA/+</italic> and <italic>plexB/+</italic>, control flies (third and fourth bars from the <italic>y</italic>-axes, respectively). For viability assays, <italic>n</italic> &gt; 100 flies per genotype; for contraction assays, <italic>n</italic> &gt; 20 larvae per genotype. Error bars represent ± SEM.</p>
</caption>
<graphic xlink:href="fnmol-11-00055-g0002"></graphic>
</fig>
</sec>
<sec id="s3-4">
<title>Plexin Levels Differentially Modify Axonal Accumulation of the Active Zone Protein Bruchpilot in Mutant GlyRS Flies</title>
<p>We next determined how altered plexin levels modify additional key phenotypes of the <italic>Drosophila</italic> CMT2D model. First, we looked at the previously described axonal accumulation of the active zone-associated protein Brp (Figures <xref ref-type="fig" rid="F3">3A–D</xref>, Supplementary Figure S4; Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>), which is a potential early indicator of neuropathology (Johnson et al., <xref ref-type="bibr" rid="B19">2009</xref>) that may be caused by axonal transport defects (Goldstein et al., <xref ref-type="bibr" rid="B11">2008</xref>). Both ubiquitous and muscle expression of mutant GlyRS lead to Brp protein accumulation in the axons of the peripheral nervous system. This appears to be driven via a non-cell autonomous mechanism as Brp build-up is not seen when mutant <italic>gars</italic> is expressed in neurons (Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>). Quantification of the number of Brp-positive foci in the region of the TN adjacent to muscle 6 and 7 was performed in GlyRS mutant flies crossed with either the plexin heterozygous loss-of-function mutants, or the plexin overexpressors. In wild-type and control flies, Brp foci are limited, but can be observed in some axons (Figure <xref ref-type="fig" rid="F3">3A</xref>; ~3 axonal foci per section in controls). This number dramatically increases when mutant <italic>gars</italic> is expressed (~20 axonal foci per section). Concordant with the differential effects on viability (Figure <xref ref-type="fig" rid="F2">2</xref>), a reduction of <italic>plexB</italic> levels reduced Brp accumulation (~12 axonal foci per section), while <italic>plexB</italic> overexpression enhanced Brp accumulation (~36 axonal foci per section; Figure <xref ref-type="fig" rid="F3">3D</xref>). Conversely, Plexin A overexpression reduced the accumulation of axonal Brp in the GlyRS mutant flies, while <italic>plexA</italic> reduction enhanced the build-up.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p><italic>plexA</italic> and <italic>plexB</italic> dosage changes modify GlyRS<sup>P234KY</sup>-associated axonal defects and mutant GlyRS accumulation at the neuromuscular junction (NMJ). <bold>(A–C)</bold> Digitally inverted images of the TN showing increased axonal bruchpilot (Brp) compared to control <bold>(A)</bold> upon ubiquitous <bold>(B)</bold> and muscle-specific <bold>(C)</bold>
<italic>gars</italic><sup>P234KY</sup> expression. <bold>(D)</bold> The build-up of Brp in axons of the TN caused by ubiquitous GlyRS<sup>P234KY</sup> expression is modulated by alterations in PlexA or PlexB levels. Greater Brp accumulation is observed upon PlexA reduction and PlexB overexpression, whereas an increase in PlexA and a decrease in PlexB ameliorate Brp build-up. N.b., <italic>gars</italic><sup>P234KY</sup> is not expressed in the <italic>plexA/+</italic> and <italic>plexB/+</italic> control flies (third and fourth bars from the <italic>y</italic>-axis, respectively).<bold> (E)</bold> An example of GlyRS<sup>P234KY</sup> (HA staining) accumulation at the presynapse when ubiquitously expressed. <bold>(F)</bold> GlyRS<sup>P234KY</sup> accumulates at the neuronal membrane, and correlates with PlexB, but not PlexA, levels, i.e., increased and decreased abundance of PlexB causes increased and decreased mutant GlyRS build-up, respectively.<bold> (G)</bold> When expressed with a ubiquitous driver, PlexB localizes at the NMJ with the neuronal marker HRP.<bold> (H)</bold> PlexB and GlyRS<sup>P234KY</sup> localize to the NMJ when co-expressed using a ubiquitous driver. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001 Dunn’s/Bonferroni’s multiple comparison test. <italic>#</italic>: displayed a significant increase when compared to the mutant GlyRS background alone (Mann-Whitney <italic>U</italic> test, <italic>P</italic> = 0.03). All experiments are performed expressing <italic>gars</italic><sup>P234KY</sup> with a ubiquitous driver (<italic>1032-GAL4</italic>). Scale bar = 10 μm. For all experiments, <italic>n</italic> &gt; 20 larvae per genotype. Error bars represent ± SEM. See also Supplementary Figure S4.</p>
</caption>
<graphic xlink:href="fnmol-11-00055-g0003"></graphic>
</fig>
</sec>
<sec id="s3-5">
<title>Plexin B Levels but Not Plexin A Modify Mutant GlyRS Accumulation at Neuromuscular Synapses</title>
<p>The neomorphic binding of mutant GlyRS to neuronal membrane proteins has been shown to be a potential mechanism for the toxic gain-of-function associated with CMT2D (He et al., <xref ref-type="bibr" rid="B15">2015</xref>; Sleigh et al., <xref ref-type="bibr" rid="B41">2017a</xref>). We therefore wanted to understand if alterations in plexin levels affect the accumulation of mutant GlyRS at the <italic>Drosophila</italic> neuromuscular synapse. We have previously reported that mutant but not wild-type GlyRS accumulates at the presynaptic NMJ in third instar larvae (Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>; Figure <xref ref-type="fig" rid="F3">3E</xref>). This build-up coincided with NMJ defects described in the same report. We found that reducing <italic>plexB</italic> decreased the intensity of mutant GlyRS staining at the presynapse (51% decrease, Figure <xref ref-type="fig" rid="F3">3F</xref>). There was a trend for <italic>plexB</italic> overexpression to increase the build-up of mutant GlyRS at the presynapse, which was significantly greater when compared is isolation to the mutant GlyRS flies (35% increase Mann-Whitney <italic>U</italic> test, <italic>P</italic> = 0.03), suggestive of a reciprocal pattern associated with down- and up-regulation of Plexin B. No significant alterations were observed with <italic>plexA</italic> reduction or overexpression, suggesting that the synaptic accumulation of mutant GlyRS is observably modified by Plexin B alone. The expression patterns of plexins, are not well understood, due in part to a lack of reliable antibodies. We therefore overexpressed myc-tagged Plexin B and found that it localized to the presynaptic neuron (Figure <xref ref-type="fig" rid="F3">3G</xref>), where it co-stained with the mutant GlyRS protein (Figure <xref ref-type="fig" rid="F3">3H</xref>). The dependence of presynaptic GlyRS accumulation on Plexin B parallels the mammalian association of mutated GlyRS with Nrp1 (He et al., <xref ref-type="bibr" rid="B15">2015</xref>).</p>
</sec>
<sec id="s3-6">
<title>Overexpression of Sema2a, the PlexB Ligand, Suppresses Mutant GlyRS-linked Neuropathology</title>
<p>If presynaptic accumulation of mutant GlyRS and the associated neuromuscular defects are dependent on the aberrant binding of mutant GlyRS to plexins, we might expect that overexpression of the natural plexin ligands could supress the disease phenotypes through competitive binding. PlexA is the receptor for transmembrane semaphorin-1a (Sema1a), while PlexB is the main receptor for the secreted semaphorin Sema2a (Winberg et al., <xref ref-type="bibr" rid="B49">1998</xref>; Ayoob et al., <xref ref-type="bibr" rid="B4">2006</xref>). To mimic the non-cell autonomous effect, we expressed both Sema1a and Sema2a using a muscle-specific driver (Figure <xref ref-type="fig" rid="F4">4</xref>). Sema1a overexpression conferred no alteration in GlyRS<sup>P234KY</sup> fly motor function (Figure <xref ref-type="fig" rid="F3">3A</xref>), axonal Brp accumulation (Figure <xref ref-type="fig" rid="F4">4B</xref>), or synaptic GlyRS build-up (Figure <xref ref-type="fig" rid="F4">4C</xref>). In addition, no further modifications were observed when Sema1a was overexpressed in the mutant <italic>gars</italic><sup>P234KY</sup>; <italic>plexA/+</italic> and mutant <italic>gars</italic><sup>P234KY</sup>; <italic>plexB/+</italic> backgrounds (Figure <xref ref-type="fig" rid="F4">4</xref>). This suggests that the mutant GlyRS pathology is not dependent on Sema1a-PlexA.</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Overexpression of the Plexin B ligand Semaphorin-2a (Sema2a) suppresses mutant GlyRS-mediated neuropathology. <bold>(A)</bold> Expressing <italic>Sema2a</italic>, but not <italic>Sema1a</italic>, in <italic>gars</italic><sup>P234KY</sup> flies (using the muscle driver <italic>MHC-GAL4</italic>) significantly alleviates mutant motor defects (compare <italic>gars</italic><sup>P234KY</sup> with <italic>gars</italic><sup>P234KY</sup>, <italic>Sema2a OE</italic>). In the <italic>plexB</italic> heterozygous loss-of-function background, this amelioration is further improved (compare <italic>gars</italic><sup>P234KY</sup>, <italic>Sema2a OE</italic> with <italic>gars</italic><sup>P234KY</sup>, <italic>Sema2a OE; plexB/+</italic>). In contrast, reduction of <italic>plexA</italic> levels abrogates the amelioration caused by <italic>Sema2a</italic> overexpression in <italic>gars</italic><sup>P234KY</sup> flies (compare <italic>gars</italic><sup>P234KY</sup>, <italic>Sema2a OE; plexA/+</italic> with <italic>gars</italic><sup>P234KY</sup> and <italic>gars</italic><sup>P234KY</sup>, <italic>Sema2a OE</italic>). <bold>(B,C)</bold> Consistent phenotype correlations were seen for both axonal Brp build-up <bold>(B)</bold> and synaptic accumulation of GlyRS<sup>P234KY</sup>
<bold>(C)</bold>. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001 Dunn’s/Bonferroni’s multiple comparison test. N.b., <italic>gars</italic><sup>P234KY</sup> is not expressed in the <italic>Sema1a OE</italic> and <italic>Sema2a OE</italic> control flies (third and seventh bars from the <italic>y</italic>-axes, respectively). All experiments are performed expressing <italic>gars</italic><sup>P234KY</sup> with a ubiquitous driver (<italic>1032-GAL4</italic>). For all experiments, <italic>n</italic> &gt; 20 larvae per genotype. Error bars represent ± SEM. See also Supplementary Figure S3.</p>
</caption>
<graphic xlink:href="fnmol-11-00055-g0004"></graphic>
</fig>
<p>In stark contrast, Sema2a overexpression ameliorated the GlyRS<sup>P234KY</sup> muscle contraction defect (Figure <xref ref-type="fig" rid="F4">4A</xref>, Supplementary Figure S4), as well as decreasing axonal Brp foci (Figure <xref ref-type="fig" rid="F4">4B</xref>) and aberrant synaptic GlyRS build-up (Figure <xref ref-type="fig" rid="F4">4C</xref>). Moreover, additive improvements in the three phenotypes occurred when mutant GlyRS and Sema2a were expressed in the plexB heterozygous mutant background (Figures <xref ref-type="fig" rid="F4">4A–C</xref>). Surprisingly, Sema2A overexpression eliminated the phenotypic enhancement in severity conferred by plexA heterozygosity. However, as a possible compensatory mechanism, <italic>plexB</italic> expression is modestly increased in <italic>plexA</italic> heterozygous flies (Supplementary Figure S3). It is therefore possible that <italic>plexA</italic> modification of the mutant GlyRS phenotype, and therefore the amelioration caused by Sema2A overexpression, is at least partially mediated through increased PlexB levels.</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>We have shown that key pathologies in a <italic>Drosophila</italic> model of CMT2D can be modified by alterations in plexin-semaphorin signaling. <italic>Drosophila</italic> possess two plexins, PlexA and PlexB, which differentially bind semaphorins to provide cell-cell communication that drives axon repulsive and attractive cues. We show that mutant GlyRS expression leads to ectopic axonal branches in the peripheral nervous system, and this phenotype is modifiable by altering the levels of the <italic>Drosophila</italic> plexins, PlexA and PlexB. We then show that heterozygous reduction of PlexB ameliorates the lethality and neuropathology caused by <italic>gars</italic><sup>P234KY</sup> expression, while PlexA reduction exacerbates the same phenotypes. In addition, PlexB, but not PlexA, appears to be important for the association of mutant GlyRS with the neuromuscular synaptic membrane. Furthermore, we found that increasing expression of the secreted PlexB ligand, Sema2a, but not the PlexA ligand, Sema1a, can also supress the mutant GlyRS binding and motor defects. Finally, we show that the fluctuations in mutant GlyRS build-up at the NMJ, caused by manipulation of plexin-semaphorin components, correlates significantly with the pathological features identified in the CMT2D model (Figures <xref ref-type="fig" rid="F5">5A,B</xref>). Taken together, these data highlight the importance of plexin-semaphorin signaling in the regulation of mutant GlyRS toxicity and accumulation, and the role of the PlexB-Sema2a on mutant GlyRS synaptic build-up.</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Synaptic accumulation of mutant GlyRS correlates with neuropathology. <bold>(A,B)</bold> Linear regression analyses identifying correlations between synaptic mutant GlyRS build-up with both muscular contractions (<bold>A</bold>, <italic>r</italic><sup>2</sup> = 0.727; <italic>P</italic> = 0.0015) and axonal Brp build-up (<bold>B</bold>, <italic>r</italic><sup>2</sup> = 0.945; <italic>P</italic> &lt; 0.001).</p>
</caption>
<graphic xlink:href="fnmol-11-00055-g0005"></graphic>
</fig>
<p>In both invertebrates and vertebrates, plexin signaling drives the attractive and repulsive signals required for high-fidelity nerve-nerve, nerve-muscle and nerve-glia interactions (Winberg et al., <xref ref-type="bibr" rid="B49">1998</xref>; Hu et al., <xref ref-type="bibr" rid="B17">2001</xref>; Ayoob et al., <xref ref-type="bibr" rid="B4">2006</xref>; Berke and Keshishian, <xref ref-type="bibr" rid="B6">2011</xref>; Roh et al., <xref ref-type="bibr" rid="B36">2016</xref>; Syed et al., <xref ref-type="bibr" rid="B46">2016</xref>). Although CMT2D is thought to be primarily degenerative in nature, neurodevelopment and maturation defects are observed in invertebrate (Grice et al., <xref ref-type="bibr" rid="B14">2015b</xref>) and vertebrate (Sleigh et al., <xref ref-type="bibr" rid="B43">2014b</xref>, <xref ref-type="bibr" rid="B41">2017a</xref>) models, with motor neuron migration (He et al., <xref ref-type="bibr" rid="B15">2015</xref>) and sensory neuron branching defects seen in mutant mouse embryos (Sleigh et al., <xref ref-type="bibr" rid="B41">2017a</xref>). It has not been established how the neurodevelopmental defects arise and whether they are a precursor to pathology, or an epiphenomenon. Our data in <italic>Drosophila</italic> indicate that mutant GlyRS interferes with the fidelity of axon guidance pathways that are partly governed by both PlexA and PlexB signaling. As mutant GlyRS expression both phenocopies and modifies the <italic>plexA</italic> and <italic>plexB</italic> axonal branching defects, we suggest that the ectopic branching phenotype arises from mutant GlyRS interaction and interference with canonical plexin signaling. Importantly, however, whilst we found opposing effects of PlexA and PlexB on toxicity phenotypes and associated pathology, the same neurodevelopment defects were exacerbated with reduction of either plexin. Hence, the data suggest that axonal guidance defects are de-coupled from the neurodegenerative pathology, mirroring the developmental switching in sensory neuron identity observed in <italic>Gars</italic> mice that appears to be independent from the progressive peripheral nerve degeneration (Sleigh et al., <xref ref-type="bibr" rid="B41">2017a</xref>).</p>
<p>In this study, we use the larval NMJ to examine the interaction between the plexin-semaphorin components and mutant GlyRS toxicity. However, unravelling the complete contribution of plexin-semaphorin signaling to CMT2D, in both the peripheral and central nervous systems, is made difficult by the complexity of the temporally and spatially diverse functions mediated through both plexin types (Neufeld et al., <xref ref-type="bibr" rid="B30">2011</xref>; Roh et al., <xref ref-type="bibr" rid="B36">2016</xref>). For example, <italic>Drosophila</italic> PlexA has been shown to drive repulsive axon guidance cues in the embryo, whilst PlexB can initiate either repulsive or attractive cell-cell interactions depending on the cellular environment (Winberg et al., <xref ref-type="bibr" rid="B49">1998</xref>; Berke and Keshishian, <xref ref-type="bibr" rid="B6">2011</xref>; Wu et al., <xref ref-type="bibr" rid="B50">2011</xref>; Jeong et al., <xref ref-type="bibr" rid="B18">2012</xref>). In addition, the repulsive and attractive actions are mediated though different ligands and interact with different downstream effectors (Winberg et al., <xref ref-type="bibr" rid="B49">1998</xref>; Hu et al., <xref ref-type="bibr" rid="B17">2001</xref>; Ayoob et al., <xref ref-type="bibr" rid="B4">2006</xref>; Bates and Whitington, <xref ref-type="bibr" rid="B5">2007</xref>; Berke and Keshishian, <xref ref-type="bibr" rid="B6">2011</xref>; Cho et al., <xref ref-type="bibr" rid="B9">2012</xref>; Roh et al., <xref ref-type="bibr" rid="B36">2016</xref>). Plexin A binds strongly to the Sema1 class of semaphorins, while Plexin B binds to the Sema2 class (Winberg et al., <xref ref-type="bibr" rid="B49">1998</xref>; Ayoob et al., <xref ref-type="bibr" rid="B4">2006</xref>; Bates and Whitington, <xref ref-type="bibr" rid="B5">2007</xref>). The plexin-semaphorin interactions occur in both competitive and cooperative processes, and can involve both forward and reverse signaling cascades. We show that overexpression of <italic>Sema2a</italic> in larval muscle suppresses the motor and neuronal phenotypes observed when mutant GlyRS is expressed. In contrast, there is no change in the phenotypic readouts when the class 1 semaphorin, Sema1A, is overexpressed. Accordingly, PlexB reduction, unlike PlexA, was able to partly rescue the mutant GlyRS lethality. We thus propose that PlexB is required for the build-up of mutant GlyRS at the NMJ, and ultimately the toxicity caused by expression of <italic>gars</italic><sup>P234KY</sup>. Mutant GlyRS could be competing with Sema2A binding at the larval NMJ, and interfere with other membrane-bound or secreted factors associated with different neuronal cell types, or at different developmental time points. It is likely that the <italic>plexB</italic> heterozygote fly did not produce a complete rescue of mutant GlyRS because <italic>plexB</italic> is still expressed, albeit at a reduced level. Consistent with a role for PlexB-mutant GlyRS binding in synaptic accumulation, the overexpression of Sema2A, particularly in the reduced <italic>plexB</italic> fly, led to further reduction in GlyRS build-up and an additive improvement in disease phenotypes, presumably by out-competing mutant GlyRS.</p>
<p>Within the cell, GlyRS charges glycine to its cognate tRNA; however, in a non-canonical tumur-defense capacity, GlyRS also binds to the extracellular receptor protein K-cadherin (Park et al., <xref ref-type="bibr" rid="B35">2012</xref>). Moreover, GlyRS functions in neddylation by interacting with NEDD8 (Mo et al., <xref ref-type="bibr" rid="B25">2016</xref>). A non-canonical neuronal receptor protein has not yet been reported for wild-type GlyRS, but mutant GlyRS has been shown to interact with multiple anomalous targets (He et al., <xref ref-type="bibr" rid="B15">2015</xref>; Sleigh et al., <xref ref-type="bibr" rid="B41">2017a</xref>). Our data suggest that Plexin B may either be an additional, or fly-specific, aberrant target, or an indirect modifier of the interactions that drive the association of mutant GlyRS with the presynaptic membrane. In mice, mutated GlyRS erroneously binds to Nrp1 and this interaction competes with the binding of the endogenous ligand VEGF (He et al., <xref ref-type="bibr" rid="B15">2015</xref>). The data we present here are similar in that an anomalous interaction between mutated GlyRS and PlexB competes with the endogenous ligand, Sema2A. Indeed, VEGF treatment partially rescues motor function of the CMT2D mice and Nrp1 heterozygosity exacerbates it (He et al., <xref ref-type="bibr" rid="B15">2015</xref>), while reduced expression of VEGF in wild-type mice has been shown to contribute to motor neuron degeneration (Oosthuyse et al., <xref ref-type="bibr" rid="B32">2001</xref>). These findings argue that in both fly and mouse, secreted mutant GlyRS interacts with neuronally-expressed transmembrane proteins involved in signaling. The downstream consequences of aberrant binding remain to be elucidated; however, the amelioration of the phenotype by reducing plexin B indicates that loss of Sema2A-PlexB signaling is not the mechanism. Instead, the strong correlation we observed between presynaptic mutant GlyRS accumulation and neuromuscular dysfunction suggests that the former is an important part of the pathogenic process (Figure <xref ref-type="fig" rid="F5">5</xref>).</p>
<p>We have suggested that Plexin B may either be an anomalous target for mutant GlyRS, or an indirect modifier of the interactions that drive the association of mutant GlyRS with the presynaptic membrane. Our data also suggest that PlexA may further modify the phenotypes indirectly through its physiological antagonism of PlexB-driven processes. Interactions of this nature have been noted previously; for example, PlexA has been shown to partially rescue the PlexB mutant, but PlexB did not reciprocally rescue PlexA mutants (Ayoob et al., <xref ref-type="bibr" rid="B4">2006</xref>). We have shown that the presence of the plexA heterozygous mutation eliminates the mutant <italic>gars</italic> phenotype amelioration conferred by Sema2A overexpression, suggesting that PlexA may act independently on mutant GlyRS toxicity at the NMJ, and downstream of PlexB. Beyond this, as multiple semophorin-plexin interactions control nerve-nerve, nerve-muscle, and nerve-glia communication (Ayoob et al., <xref ref-type="bibr" rid="B4">2006</xref>; Bates and Whitington, <xref ref-type="bibr" rid="B5">2007</xref>; Yu et al., <xref ref-type="bibr" rid="B52">2010</xref>; Syed et al., <xref ref-type="bibr" rid="B46">2016</xref>), a range of parallel mechanisms may cause defects that ultimately lead to broader changes in the set-up and maintenance of neuronal circuits and synapses of the animal. Moreover, additional signaling pathways may drive parallel neuroprotective actions within the nervous system, and therefore titre mutant GlyRS binding and toxicity further.</p>
<p>In summary, we have shown that mutants GlyRS expression interferes with plexin-mediated axonal branching, and that the alteration of plexin-semaphorin signaling can modify mutant GlyRS lethality, neuromuscular dysfunction, and neuropathology. This toxic gain-of-function, and alteration of neurodevelopmental pathways, highlights mechanisms analogous to a mammalian model of the disease. Our findings provide additional evidence of a new disease paradigm in CMT2D, which provides further explanation for the selective effect on the nervous system of mutations in a widely expressed protein.</p>
</sec>
<sec id="s5">
<title>Author Contributions</title>
<p>SJG, JNS and MZC designed the experiments and wrote the article. SJG and JNS performed the experiments and analyzed the data. All authors have approved submission of this work.</p>
</sec>
<sec id="s6">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>The authors would like to thank Andrew R. Bassett, Robert W. Burgess, Carmen H. Coxon, Jinghuan Li, Gregory A. Weir and Xiang-Lei Yang for sharing preliminary data, experimental advice and productive discussions.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported by the UK Medical Research Council (SJG, MZC); the Oxford Biomedical Research Centre (MZC); the French Muscular Dystrophy Association (AFM-Téléthon; JNS, MZC); and a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellowship (103191/A/13/Z; JNS). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.</p>
</fn>
</fn-group>
<sec id="s7" sec-type="supplementary material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fnmol.2018.00055/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fnmol.2018.00055/full#supplementary-material</ext-link></p>
<supplementary-material content-type="local-data" id="SM1">
<media xlink:href="Image_1.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achilli</surname><given-names>F.</given-names></name><name><surname>Bros-Facer</surname><given-names>V.</given-names></name><name><surname>Williams</surname><given-names>H. P.</given-names></name><name><surname>Banks</surname><given-names>G. T.</given-names></name><name><surname>AlQatari</surname><given-names>M.</given-names></name><name><surname>Chia</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>An ENU-induced mutation in mouse glycyl-tRNA synthetase (<italic>GARS</italic>) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy</article-title>. <source/>Dis. Model. Mech.
<volume>2</volume>, <fpage>359</fpage>–<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1242/dmm.002527</pub-id><pub-id pub-id-type="pmid">19470612</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrova</surname><given-names>J.</given-names></name><name><surname>Paulus</surname><given-names>C.</given-names></name><name><surname>Rudinger-Thirion</surname><given-names>J.</given-names></name><name><surname>Jossinet</surname><given-names>F.</given-names></name><name><surname>Frugier</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Elaborate uORF/IRES features control expression and localization of human glycyl-tRNA synthetase</article-title>. <source/>RNA Biol.
<volume>12</volume>, <fpage>1301</fpage>–<lpage>1313</lpage>. <pub-id pub-id-type="doi">10.1080/15476286.2015.1086866</pub-id><pub-id pub-id-type="pmid">26327585</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonellis</surname><given-names>A.</given-names></name><name><surname>Ellsworth</surname><given-names>R. E.</given-names></name><name><surname>Sambuughin</surname><given-names>N.</given-names></name><name><surname>Puls</surname><given-names>I.</given-names></name><name><surname>Abel</surname><given-names>A.</given-names></name><name><surname>Lee-Lin</surname><given-names>S. Q.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V</article-title>. <source/>Am. J. Hum. Genet.
<volume>72</volume>, <fpage>1293</fpage>–<lpage>1299</lpage>. <pub-id pub-id-type="doi">10.1086/375039</pub-id><pub-id pub-id-type="pmid">12690580</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayoob</surname><given-names>J. C.</given-names></name><name><surname>Terman</surname><given-names>J. R.</given-names></name><name><surname>Kolodkin</surname><given-names>A. L.</given-names></name></person-group> (<year>2006</year>). <article-title><italic>Drosophila</italic> Plexin B is a Sema-2a receptor required for axon guidance</article-title>. <source/>Development
<volume>133</volume>, <fpage>2125</fpage>–<lpage>2135</lpage>. <pub-id pub-id-type="doi">10.1242/dev.02380</pub-id><pub-id pub-id-type="pmid">16672342</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>K. E.</given-names></name><name><surname>Whitington</surname><given-names>P. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Semaphorin 2a secreted by oenocytes signals through plexin B and plexin A to guide sensory axons in the <italic>Drosophila</italic> embryo</article-title>. <source/>Dev. Biol.
<volume>302</volume>, <fpage>522</fpage>–<lpage>535</lpage>. <pub-id pub-id-type="doi">10.1016/j.ydbio.2006.10.015</pub-id><pub-id pub-id-type="pmid">17109838</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berke</surname><given-names>B.</given-names></name><name><surname>Keshishian</surname><given-names>H.</given-names></name></person-group> (<year>2011</year>). <article-title>Cracking the combinatorial semaphorin code</article-title>. <source/>Neuron
<volume>70</volume>, <fpage>175</fpage>–<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.04.010</pub-id><pub-id pub-id-type="pmid">21521607</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrillo</surname><given-names>R. A.</given-names></name><name><surname>Olsen</surname><given-names>D. P.</given-names></name><name><surname>Yoon</surname><given-names>K. S.</given-names></name><name><surname>Keshishian</surname><given-names>H.</given-names></name></person-group> (<year>2010</year>). <article-title>Presynaptic activity and CaMKII modulate retrograde semaphorin signaling and synaptic refinement</article-title>. <source/>Neuron
<volume>68</volume>, <fpage>32</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.005</pub-id><pub-id pub-id-type="pmid">20920789</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chihara</surname><given-names>T.</given-names></name><name><surname>Luginbuhl</surname><given-names>D.</given-names></name><name><surname>Luo</surname><given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>Cytoplasmic and mitochondrial protein translation in axonal and dendritic terminal arborization</article-title>. <source/>Nat. Neurosci.
<volume>10</volume>, <fpage>828</fpage>–<lpage>837</lpage>. <pub-id pub-id-type="doi">10.1038/nn1910</pub-id><pub-id pub-id-type="pmid">17529987</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>J. Y.</given-names></name><name><surname>Chak</surname><given-names>K.</given-names></name><name><surname>Andreone</surname><given-names>B. J.</given-names></name><name><surname>Wooley</surname><given-names>J. R.</given-names></name><name><surname>Kolodkin</surname><given-names>A. L.</given-names></name></person-group> (<year>2012</year>). <article-title>The extracellular matrix proteoglycan perlecan facilitates transmembrane semaphorin-mediated repulsive guidance</article-title>. <source/>Genes Dev.
<volume>26</volume>, <fpage>2222</fpage>–<lpage>2235</lpage>. <pub-id pub-id-type="doi">10.1101/gad.193136.112</pub-id><pub-id pub-id-type="pmid">23028146</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ermanoska</surname><given-names>B.</given-names></name><name><surname>Motley</surname><given-names>W. W.</given-names></name><name><surname>Leitao-Goncalves</surname><given-names>R.</given-names></name><name><surname>Asselbergh</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>L. H.</given-names></name><name><surname>De Rijk</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>CMT-associated mutations in glycyl- and tyrosyl-tRNA synthetases exhibit similar pattern of toxicity and share common genetic modifiers in <italic>Drosophila</italic></article-title>. <source/>Neurobiol. Dis.
<volume>68</volume>, <fpage>180</fpage>–<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2014.04.020</pub-id><pub-id pub-id-type="pmid">24807208</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>A. Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Schwarz</surname><given-names>T. L.</given-names></name></person-group> (<year>2008</year>). <article-title>Axonal transport and the delivery of pre-synaptic components</article-title>. <source/>Curr. Opin. Neurobiol.
<volume>18</volume>, <fpage>495</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2008.10.003</pub-id><pub-id pub-id-type="pmid">18950710</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>M.</given-names></name><name><surname>McLaughlin</surname><given-names>H.</given-names></name><name><surname>Houlden</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>M.</given-names></name><name><surname>Yo-Tsen</surname><given-names>L.</given-names></name><name><surname>Hadjivassilious</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (<italic>MARS</italic>) in a family with late-onset CMT2</article-title>. <source/>J. Neurol. Neurosurg. Psychiatry
<volume>84</volume>, <fpage>1247</fpage>–<lpage>1249</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp-2013-305049</pub-id><pub-id pub-id-type="pmid">23729695</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grice</surname><given-names>S. J.</given-names></name><name><surname>Liu</surname><given-names>J. L.</given-names></name><name><surname>Webber</surname><given-names>C.</given-names></name></person-group> (<year>2015a</year>). <article-title>Synergistic interactions between <italic>Drosophila</italic> orthologues of genes spanned by de novo human CNVs support multiple-hit models of autism</article-title>. <source/>PLoS Genet.
<volume>11</volume>:<fpage>e1004998</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1004998</pub-id><pub-id pub-id-type="pmid">25816101</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grice</surname><given-names>S. J.</given-names></name><name><surname>Sleigh</surname><given-names>J. N.</given-names></name><name><surname>Motley</surname><given-names>W. W.</given-names></name><name><surname>Liu</surname><given-names>J. L.</given-names></name><name><surname>Burgess</surname><given-names>R. W.</given-names></name><name><surname>Talbot</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2015b</year>). <article-title>Dominant, toxic gain-of-function mutations in gars lead to non-cell autonomous neuropathology</article-title>. <source/>Hum. Mol. Genet.
<volume>24</volume>, <fpage>4397</fpage>–<lpage>4406</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddv176</pub-id><pub-id pub-id-type="pmid">25972375</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Bai</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Wei</surname><given-names>N.</given-names></name><name><surname>White</surname><given-names>N. M.</given-names></name><name><surname>Lauer</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase</article-title>. <source/>Nature
<volume>526</volume>, <fpage>710</fpage>–<lpage>714</lpage>. <pub-id pub-id-type="doi">10.1038/nature15510</pub-id><pub-id pub-id-type="pmid">26503042</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>H. M.</given-names></name><name><surname>Chong</surname><given-names>Y. E.</given-names></name><name><surname>Guo</surname><given-names>M.</given-names></name><name><surname>Marshall</surname><given-names>A. G.</given-names></name><name><surname>Yang</surname><given-names>X. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Dispersed disease-causing neomorphic mutations on a single protein promote the same localized conformational opening</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>108</volume>, <fpage>12307</fpage>–<lpage>12312</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1104293108</pub-id><pub-id pub-id-type="pmid">21737751</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Marton</surname><given-names>T. F.</given-names></name><name><surname>Goodman</surname><given-names>C. S.</given-names></name></person-group> (<year>2001</year>). <article-title>Plexin B mediates axon guidance in <italic>Drosophila</italic> by simultaneously inhibiting active Rac and enhancing RhoA signaling</article-title>. <source/>Neuron
<volume>32</volume>, <fpage>39</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/s0896-6273(01)00453-6</pub-id><pub-id pub-id-type="pmid">11604137</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>S.</given-names></name><name><surname>Juhaszova</surname><given-names>K.</given-names></name><name><surname>Kolodkin</surname><given-names>A. L.</given-names></name></person-group> (<year>2012</year>). <article-title>The Control of semaphorin-1a-mediated reverse signaling by opposing pebble and RhoGAPp190 functions in <italic>Drosophila</italic></article-title>. <source/>Neuron
<volume>76</volume>, <fpage>721</fpage>–<lpage>734</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.09.018</pub-id><pub-id pub-id-type="pmid">23177958</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>E. L.</given-names><suffix>III.</suffix></name><name><surname>Fetter</surname><given-names>R. D.</given-names></name><name><surname>Davis</surname><given-names>G. W.</given-names></name></person-group> (<year>2009</year>). <article-title>Negative regulation of active zone assembly by a newly identified SR protein kinase</article-title>. <source/>PLoS Biol.
<volume>7</volume>:<fpage>e1000193</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.1000193</pub-id><pub-id pub-id-type="pmid">19771148</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordanova</surname><given-names>A.</given-names></name><name><surname>Irobi</surname><given-names>J.</given-names></name><name><surname>Thomas</surname><given-names>F. P.</given-names></name><name><surname>Van Dijck</surname><given-names>P.</given-names></name><name><surname>Meerschaert</surname><given-names>K.</given-names></name><name><surname>Dewil</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy</article-title>. <source/>Nat. Genet.
<volume>38</volume>, <fpage>197</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1038/ng1727</pub-id><pub-id pub-id-type="pmid">16429158</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latour</surname><given-names>P.</given-names></name><name><surname>Thauvin-Robinet</surname><given-names>C.</given-names></name><name><surname>Baudelet-Mery</surname><given-names>C.</given-names></name><name><surname>Soichot</surname><given-names>P.</given-names></name><name><surname>Cusin</surname><given-names>V.</given-names></name><name><surname>Faivre</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>A major determinant for binding and aminoacylation of tRNA(Ala) in cytoplasmic Alanyl-tRNA synthetase is mutated in dominant axonal Charcot-Marie-Tooth disease</article-title>. <source/>Am. J. Hum. Genet.
<volume>86</volume>, <fpage>77</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2009.12.005</pub-id><pub-id pub-id-type="pmid">20045102</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Sayin</surname><given-names>A.</given-names></name><name><surname>Cauchi</surname><given-names>R. J.</given-names></name><name><surname>Grice</surname><given-names>S.</given-names></name><name><surname>Burdett</surname><given-names>H.</given-names></name><name><surname>Baban</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Genome-wide expression analysis of a spinal muscular atrophy model: towards discovery of new drug targets</article-title>. <source/>PLoS One
<volume>3</volume>:<fpage>e1404</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0001404</pub-id><pub-id pub-id-type="pmid">18167563</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsay</surname><given-names>R. M.</given-names></name></person-group> (<year>1996</year>). <article-title>Role of neurotrophins and trk receptors in the development and maintenance of sensory neurons: an overview</article-title>. <source/>Philos. Trans. R. Soc. Lond. B Biol. Sci.
<volume>351</volume>, <fpage>365</fpage>–<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1098/rstb.1996.0030</pub-id><pub-id pub-id-type="pmid">8730773</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>H. M.</given-names></name><name><surname>Sakaguchi</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Igarashi</surname><given-names>T.</given-names></name><name><surname>Pehlivan</surname><given-names>D.</given-names></name><name><surname>Chu</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy</article-title>. <source/>Am. J. Hum. Genet.
<volume>87</volume>, <fpage>560</fpage>–<lpage>566</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2010.09.008</pub-id><pub-id pub-id-type="pmid">20920668</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Lauer</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Neddylation requires glycyl-tRNA synthetase to protect activated E2</article-title>. <source/>Nat. Struct. Mol. Biol.
<volume>23</volume>, <fpage>730</fpage>–<lpage>737</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.3250</pub-id><pub-id pub-id-type="pmid">27348078</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motley</surname><given-names>W. W.</given-names></name><name><surname>Seburn</surname><given-names>K. L.</given-names></name><name><surname>Nawaz</surname><given-names>M. H.</given-names></name><name><surname>Miers</surname><given-names>K. E.</given-names></name><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Antonellis</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Charcot-Marie-Tooth-linked mutant GARS is toxic to peripheral neurons independent of wild-type GARS levels</article-title>. <source/>PLoS Genet.
<volume>7</volume>:<fpage>e1002399</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1002399</pub-id><pub-id pub-id-type="pmid">22144914</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motley</surname><given-names>W. W.</given-names></name><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Fischbeck</surname><given-names>K. H.</given-names></name></person-group> (<year>2010</year>). <article-title><italic>GARS</italic> axonopathy: not every neuron’s cup of tRNA</article-title>. <source/>Trends Neurosci.
<volume>33</volume>, <fpage>59</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2009.11.001</pub-id><pub-id pub-id-type="pmid">20152552</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nangle</surname><given-names>L. A.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>X. L.</given-names></name><name><surname>Schimmel</surname><given-names>P.</given-names></name></person-group> (<year>2007</year>). <article-title>Charcot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>104</volume>, <fpage>11239</fpage>–<lpage>11244</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0705055104</pub-id><pub-id pub-id-type="pmid">17595294</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neufeld</surname><given-names>G.</given-names></name><name><surname>Cohen</surname><given-names>T.</given-names></name><name><surname>Shraga</surname><given-names>N.</given-names></name><name><surname>Lange</surname><given-names>T.</given-names></name><name><surname>Kessler</surname><given-names>O.</given-names></name><name><surname>Herzog</surname><given-names>Y.</given-names></name></person-group> (<year>2002</year>). <article-title>The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis</article-title>. <source/>Trends Cardiovasc. Med.
<volume>12</volume>, <fpage>13</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/s1050-1738(01)00140-2</pub-id><pub-id pub-id-type="pmid">11796239</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neufeld</surname><given-names>S. Q.</given-names></name><name><surname>Hibbert</surname><given-names>A. D.</given-names></name><name><surname>Chen</surname><given-names>B. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Opposing roles of PlexinA and PlexinB in axonal branch and varicosity formation</article-title>. <source/>Mol. Brain
<volume>4</volume>:<fpage>15</fpage>. <pub-id pub-id-type="doi">10.1186/1756-6606-4-15</pub-id><pub-id pub-id-type="pmid">21489263</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niehues</surname><given-names>S.</given-names></name><name><surname>Bussmann</surname><given-names>J.</given-names></name><name><surname>Steffes</surname><given-names>G.</given-names></name><name><surname>Erdmann</surname><given-names>I.</given-names></name><name><surname>Köhrer</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Impaired protein translation in <italic>Drosophila</italic> models for Charcot-Marie-Tooth neuropathy caused by mutant tRNA synthetases</article-title>. <source/>Nat. Commun.
<volume>6</volume>:<fpage>7520</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms8520</pub-id><pub-id pub-id-type="pmid">26138142</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oosthuyse</surname><given-names>B.</given-names></name><name><surname>Moons</surname><given-names>L.</given-names></name><name><surname>Storkebaum</surname><given-names>E.</given-names></name><name><surname>Beck</surname><given-names>H.</given-names></name><name><surname>Nuyens</surname><given-names>D.</given-names></name><name><surname>Brusselmans</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration</article-title>. <source/>Nat. Genet.
<volume>28</volume>, <fpage>131</fpage>–<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1038/88842</pub-id><pub-id pub-id-type="pmid">11381259</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orr</surname><given-names>B. O.</given-names></name><name><surname>Fetter</surname><given-names>R. D.</given-names></name><name><surname>Davis</surname><given-names>G. W.</given-names></name></person-group> (<year>2017</year>). <article-title>Retrograde semaphorin-plexin signalling drives homeostatic synaptic plasticity</article-title>. <source/>Nature
<volume>550</volume>, <fpage>109</fpage>–<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1038/nature24017</pub-id><pub-id pub-id-type="pmid">28953869</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>Y. L.</given-names></name><name><surname>Poruri</surname><given-names>K.</given-names></name><name><surname>Martinis</surname><given-names>S. A.</given-names></name></person-group> (<year>2014</year>). <article-title>tRNA synthetase: tRNA aminoacylation and beyond</article-title>. <source/>Wiley Interdiscip. Rev. RNA
<volume>5</volume>, <fpage>461</fpage>–<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1002/wrna.1224</pub-id><pub-id pub-id-type="pmid">24706556</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>M. C.</given-names></name><name><surname>Kang</surname><given-names>T.</given-names></name><name><surname>Jin</surname><given-names>D.</given-names></name><name><surname>Han</surname><given-names>J. M.</given-names></name><name><surname>Kim</surname><given-names>S. B.</given-names></name><name><surname>Park</surname><given-names>Y. J.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>109</volume>, <fpage>E640</fpage>–<lpage>E647</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1200194109</pub-id><pub-id pub-id-type="pmid">22345558</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roh</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>D. S.</given-names></name><name><surname>Jeong</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Differential ligand regulation of PlexB signaling in motor neuron axon guidance in <italic>Drosophila</italic></article-title>. <source/>Int. J. Dev. Neurosci.
<volume>55</volume>, <fpage>34</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijdevneu.2016.09.006</pub-id><pub-id pub-id-type="pmid">27637927</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>C. M.</given-names></name><name><surname>Davis</surname><given-names>G. W.</given-names></name><name><surname>Fetter</surname><given-names>R. D.</given-names></name><name><surname>Goodman</surname><given-names>C. S.</given-names></name></person-group> (<year>1996</year>). <article-title>Genetic dissection of structural and functional components of synaptic plasticity. I. Fasciclin II controls synaptic stabilization and growth</article-title>. <source/>Neuron
<volume>17</volume>, <fpage>641</fpage>–<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1016/s0896-6273(00)80199-3</pub-id><pub-id pub-id-type="pmid">8893022</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seburn</surname><given-names>K. L.</given-names></name><name><surname>Nangle</surname><given-names>L. A.</given-names></name><name><surname>Cox</surname><given-names>G. A.</given-names></name><name><surname>Schimmel</surname><given-names>P.</given-names></name><name><surname>Burgess</surname><given-names>R. W.</given-names></name></person-group> (<year>2006</year>). <article-title>An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model</article-title>. <source/>Neuron
<volume>51</volume>, <fpage>715</fpage>–<lpage>726</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2006.08.027</pub-id><pub-id pub-id-type="pmid">16982418</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivakumar</surname><given-names>K.</given-names></name><name><surname>Kyriakides</surname><given-names>T.</given-names></name><name><surname>Puls</surname><given-names>I.</given-names></name><name><surname>Nicholson</surname><given-names>G. A.</given-names></name><name><surname>Funalot</surname><given-names>B.</given-names></name><name><surname>Antonellis</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations</article-title>. <source/>Brain
<volume>128</volume>, <fpage>2304</fpage>–<lpage>2314</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awh590</pub-id><pub-id pub-id-type="pmid">16014653</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sleigh</surname><given-names>J. N.</given-names></name><name><surname>Barreiro-Iglesias</surname><given-names>A.</given-names></name><name><surname>Oliver</surname><given-names>P. L.</given-names></name><name><surname>Biba</surname><given-names>A.</given-names></name><name><surname>Becker</surname><given-names>T.</given-names></name><name><surname>Davies</surname><given-names>K. E.</given-names></name><etal></etal></person-group>. (<year>2014a</year>). <article-title>Chondrolectin affects cell survival and neuronal outgrowth in <italic>in vitro</italic> and <italic>in vivo</italic> models of spinal muscular atrophy</article-title>. <source/>Hum. Mol. Genet.
<volume>23</volume>, <fpage>855</fpage>–<lpage>869</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddt477</pub-id><pub-id pub-id-type="pmid">24067532</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sleigh</surname><given-names>J. N.</given-names></name><name><surname>Grice</surname><given-names>S. J.</given-names></name><name><surname>Burgess</surname><given-names>R. W.</given-names></name><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Cader</surname><given-names>M. Z.</given-names></name></person-group> (<year>2014b</year>). <article-title>Neuromuscular junction maturation defects precede impaired lower motor neuron connectivity in Charcot-Marie-Tooth type 2D mice</article-title>. <source/>Hum. Mol. Genet.
<volume>23</volume>, <fpage>2639</fpage>–<lpage>2650</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddt659</pub-id><pub-id pub-id-type="pmid">24368416</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sleigh</surname><given-names>J. N.</given-names></name><name><surname>Dawes</surname><given-names>J. M.</given-names></name><name><surname>West</surname><given-names>S. J.</given-names></name><name><surname>Wei</surname><given-names>N.</given-names></name><name><surname>Spaulding</surname><given-names>E. L.</given-names></name><name><surname>Gomez-Martin</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2017a</year>). <article-title>Trk receptor signaling and sensory neuron fate are perturbed in human neuropathy caused by Gars mutations</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>114</volume>, <fpage>E3324</fpage>–<lpage>E3333</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1614557114</pub-id><pub-id pub-id-type="pmid">28351971</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sleigh</surname><given-names>J. N.</given-names></name><name><surname>Gomez-Martín</surname><given-names>A.</given-names></name><name><surname>Wei</surname><given-names>N.</given-names></name><name><surname>Bai</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>X. L.</given-names></name><name><surname>Schiavo</surname><given-names>G.</given-names></name></person-group> (<year>2017b</year>). <article-title>Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular homeostasis</article-title>. <source/>Sci. Rep.
<volume>7</volume>:<fpage>9216</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-10005-w</pub-id><pub-id pub-id-type="pmid">28835631</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaulding</surname><given-names>E. L.</given-names></name><name><surname>Sleigh</surname><given-names>J. N.</given-names></name><name><surname>Morelli</surname><given-names>K. H.</given-names></name><name><surname>Pinter</surname><given-names>M. J.</given-names></name><name><surname>Burgess</surname><given-names>R. W.</given-names></name><name><surname>Seburn</surname><given-names>K. L.</given-names></name></person-group> (<year>2016</year>). <article-title>Synaptic deficits at neuromuscular junctions in two mouse models of charcot-marie-tooth type 2d</article-title>. <source/>J. Neurosci.
<volume>36</volume>, <fpage>3254</fpage>–<lpage>3267</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.1762-15.2016</pub-id><pub-id pub-id-type="pmid">26985035</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storkebaum</surname><given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>Peripheral neuropathy via mutant tRNA synthetases: Inhibition of protein translation provides a possible explanation</article-title>. <source/>Bioessays
<volume>38</volume>, <fpage>818</fpage>–<lpage>829</lpage>. <pub-id pub-id-type="doi">10.1002/bies.201600052</pub-id><pub-id pub-id-type="pmid">27352040</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Syed</surname><given-names>D. S.</given-names></name><name><surname>Gowda</surname><given-names>S. B.</given-names></name><name><surname>Reddy</surname><given-names>O. V.</given-names></name><name><surname>Reichert</surname><given-names>H.</given-names></name><name><surname>VijayRaghavan</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>Glial and neuronal Semaphorin signaling instruct the development of a functional myotopic map for <italic>Drosophila</italic> walking</article-title>. <source/>Elife
<volume>5</volume>:<fpage>e11572</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.11572</pub-id><pub-id pub-id-type="pmid">26926907</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>T. S.</given-names></name><name><surname>Kolodkin</surname><given-names>A. L.</given-names></name><name><surname>Bharadwaj</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>Semaphorin regulation of cellular morphology</article-title>. <source/>Annu. Rev. Cell Dev. Biol.
<volume>23</volume>, <fpage>263</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.cellbio.22.010605.093554</pub-id><pub-id pub-id-type="pmid">17539753</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vester</surname><given-names>A.</given-names></name><name><surname>Velez-Ruiz</surname><given-names>G.</given-names></name><name><surname>McLaughlin</surname><given-names>H. M.</given-names></name><collab>NISC Comparative Sequencing Program</collab><name><surname>Lupski</surname><given-names>J. R.</given-names></name><name><surname>Talbot</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>A loss-of-function variant in the human histidyl-tRNA synthetase (<italic>HARS</italic>) gene is neurotoxic <italic>in vivo</italic></article-title>. <source/>Hum. Mutat.
<volume>34</volume>, <fpage>191</fpage>–<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1002/humu.22210</pub-id><pub-id pub-id-type="pmid">22930593</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winberg</surname><given-names>M. L.</given-names></name><name><surname>Noordermeer</surname><given-names>J. N.</given-names></name><name><surname>Tamagnone</surname><given-names>L.</given-names></name><name><surname>Comoglio</surname><given-names>P. M.</given-names></name><name><surname>Spriggs</surname><given-names>M. K.</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>1998</year>). <article-title>Plexin A is a neuronal semaphorin receptor that controls axon guidance</article-title>. <source/>Cell
<volume>95</volume>, <fpage>903</fpage>–<lpage>916</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)81715-8</pub-id><pub-id pub-id-type="pmid">9875845</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Sweeney</surname><given-names>L. B.</given-names></name><name><surname>Ayoob</surname><given-names>J. C.</given-names></name><name><surname>Chak</surname><given-names>K.</given-names></name><name><surname>Andreone</surname><given-names>B. J.</given-names></name><name><surname>Ohyama</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>A combinatorial semaphorin code instructs the initial steps of sensory circuit assembly in the <italic>Drosophila</italic> CNS</article-title>. <source/>Neuron
<volume>70</volume>, <fpage>281</fpage>–<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.02.050</pub-id><pub-id pub-id-type="pmid">21521614</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Nangle</surname><given-names>L. A.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Schimmel</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X. L.</given-names></name></person-group> (<year>2007</year>). <article-title>Long-range structural effects of a Charcot-Marie-Tooth disease-causing mutation in human glycyl-tRNA synthetase</article-title>. <source/>Proc. Natl. Acad. Sci. U S A
<volume>104</volume>, <fpage>9976</fpage>–<lpage>9981</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0703908104</pub-id><pub-id pub-id-type="pmid">17545306</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>S.</given-names></name><name><surname>Rao</surname><given-names>Y.</given-names></name></person-group> (<year>2010</year>). <article-title>Plexin a-semaphorin-1a reverse signaling regulates photoreceptor axon guidance in <italic>Drosophila</italic></article-title>. <source/>J. Neurosci.
<volume>30</volume>, <fpage>12151</fpage>–<lpage>12156</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.1494-10.2010</pub-id><pub-id pub-id-type="pmid">20826677</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>